Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

NCT03070392 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

378

Enrollment

INDUSTRY

Sponsor class

Conditions

Uveal Melanoma

Interventions

BIOLOGICAL: IMCgp100
DRUG: Dacarbazine
BIOLOGICAL: Ipilimumab
BIOLOGICAL: Pembrolizumab

Sponsor

Immunocore Ltd